Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
cAMP response element-binding protein-regulated transcription co-activator 1 (CRTC1) is a key transcriptional co-activator that mediates cellular responses to cAMP and calcium signaling by enhancing the activity of the CREB transcription factor [1, 3]. Under basal conditions, CRTC1 is phosphorylated by Salt-inducible kinases (SIKs) and sequestered in the cytoplasm; upon activation, it is dephosphorylated by calcineurin and translocates to the nucleus to bind CREB and promote the expression of genes involved in metabolism, memory, and circadian rhythms [1, 7, 12]. In clinical oncology, CRTC1 is most prominent as a fusion partner, where the CRTC1-MAML2 translocation acts as the primary driver for mucoepidermoid carcinoma, a common salivary gland malignancy [13, 15]. Additionally, novel fusions like CRTC1-TRIM11 have been identified as drivers in specific cutaneous melanocytic tumors [17, 18]. Beyond cancer, CRTC1 dysregulation is implicated in neurodegenerative conditions like Alzheimer's disease and metabolic disorders like obesity [6, 10]. While direct pharmacological inhibition of CRTC1 remains a therapeutic challenge, experimental small molecules like 666-15 target its interaction with CREB, and indirect modulation is explored via SIK inhibitors or downstream targeting of CRTC1 fusion signaling pathways [13, 16].
CRTC1 acts as a co-activator by binding to the basic leucine zipper (bZIP) domain of the transcription factor CREB (cAMP response element-binding protein), thereby enhancing its ability to recruit the transcriptional machinery (such as TAF4 and CBP/p300) to cAMP-responsive elements (CRE) in target gene promoters [1, 3, 7]. Its activity is regulated by its subcellular localization: phosphorylation by Salt-inducible kinases (SIK) leads to cytoplasmic sequestration by 14-3-3 proteins, while dephosphorylation by calcineurin triggers nuclear translocation and activation [1, 3, 12].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cAMP response element-binding protein-regulated transcription co-activator 1 (CRTC1).